Merck & Co., Inc. (MRK)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $363.04B
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Latest financial period: June 30, 2026
Filed with the SEC: August 7, 2026
Estimated earnings date: October 29, 2026
Profit #585 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 61.4% | 78.9% | 89.7% | 88.3% |
Growth #1067 of 1484 companies
Payout #432 of 1484 companies
Safety #573 of 1484 companies
Price #1015 of 1484 companies
